Twist Bioscience Corp’s recent filing unveils that its Officer Leproust Emily M. acquired Company’s shares for reported $74139.0 on Dec 08 ’25. In the deal valued at $32.88 per share,2,255 shares were bought.
Then, Cho Dennis bought 398 shares, generating $13,085 in total proceeds.
Before that, Green Paula bought 877 shares. Twist Bioscience Corp shares valued at $28,834 were divested by the Officer at a price of $32.88 per share.
Stephens initiated its Twist Bioscience Corp [TWST] rating to an Overweight in a research note published on November 04, 2025; the price target was $41. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Guggenheim began covering TWST with “Buy” recommendation on June 04, 2024. Goldman revised its rating on January 17, 2024. It rated TWST as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TWST
On Tuesday, Twist Bioscience Corp [NASDAQ:TWST] saw its stock fall -1.99% to $31.58. Over the last five days, the stock has gained 6.33%. Twist Bioscience Corp shares have fallen nearly -37.76% since the year began. Nevertheless, the stocks have fallen -32.04% over the past one year. While a 52-week high of $55.33 was reached on 01/24/25, a 52-week low of $23.30 was recorded on 11/14/25.
Levels Of Support And Resistance For TWST Stock
The 24-hour chart illustrates a support level at 30.99, which if violated will result in even more drops to 30.40. On the upside, there is a resistance level at 32.37. A further resistance level may holdings at 33.17.
How much short interest is there in Twist Bioscience Corp?
A steep rise in short interest was recorded in Twist Bioscience Corp stocks on 2025-11-14, growing by 38200.0 shares to a total of 10.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 10.86 million shares. There was a rise of 0.35%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 27, 2023 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
